Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0CWQAC
ADC Name
FOLR1-ADC 15
Synonyms
FOLR1 ADC 15
   Click to Show/Hide
Drug Status
Investigative
Indication
In total 2 Indication(s)
Cervical cancer [ICD11:2C77]
Investigative
Ovarian cancer [ICD11:2C73]
Investigative
Drug-to-Antibody Ratio
3.2
Antibody Name
Anti-FOLR1 mAb
  Antibody Info 
Antigen Name
Folate receptor alpha (FOLR1)
  Antigen Info 
Payload Name
PBD dimer 13c
  Payload Info 
Therapeutic Target
Human Deoxyribonucleic acid (hDNA)
  Target Info 
Linker Name
Adipic acid-Val-CIt-PABC
  Linker Info 
Conjugate Type
Random conjugation through nucleophilic lysines.
General Information of The Activity Data Related to This ADC
Discovered Using Patient-derived Xenograft Model
Click To Hide/Show 6 Activity Data Related to This Level
Standard Type Value Units Animal Model (No. of PDX)
Tumor Growth Inhibition value (TGI) 
≈ 70.6
%
Ovarian cancer PDX model (PDX: OV90)
Tumor Growth Inhibition value (TGI) 
≈ 94.27
%
Ovarian cancer PDX model (PDX: OV90)
Tumor Growth Inhibition value (TGI) 
≈ 100
%
Ovarian cancer PDX model (PDX: OV90)
Tumor Growth Inhibition value (TGI) 
≈ 100
%
Ovarian cancer PDX model (PDX: OV90)
Tumor Growth Inhibition value (TGI) 
≈ 100
%
Ovarian cancer PDX model (PDX: OV90)
Tumor Growth Inhibition value (TGI) 
≈ 100
%
Ovarian cancer PDX model (PDX: OV90)
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Patient-derived Xenograft Model
Click To Hide/Show 6 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 70.60% (Day 95) Low FOLR1 expression (FOLR1+)
Method Description
SCID mice bearing OV90 subcutaneous ovarian xenografts, which express folate receptor alpha heterogeneously, at a very low level (H-Score 40)16 were treated with ADC 15 (DAR 3.2).as treatment with a single i.v. dose of 0.7 mg/kg.
In Vivo Model Ovarian cancer PDX model (PDX: OV90)
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 94.27% (Day 95) Low FOLR1 expression (FOLR1+)
Method Description
SCID mice bearing OV90 subcutaneous ovarian xenografts, which express folate receptor alpha heterogeneously, at a very low level (H-Score 40)16 were treated with ADC 15 (DAR 3.2).as treatment with a single i.v. dose of 1.4 mg/kg.
In Vivo Model Ovarian cancer PDX model (PDX: OV90)
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 100.00% (Day 35) Low FOLR1 expression (FOLR1+)
Method Description
SCID mice bearing OV90 subcutaneous ovarian xenografts, which express folate receptor alpha heterogeneously, at a very low level (H-Score 40)16 were treated with ADC 15 (DAR 3.2).as treatment with a single i.v. dose of 0.7 mg/kg.
In Vivo Model Ovarian cancer PDX model (PDX: OV90)
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 100.00% (Day 35) Low FOLR1 expression (FOLR1+)
Method Description
SCID mice bearing OV90 subcutaneous ovarian xenografts, which express folate receptor alpha heterogeneously, at a very low level (H-Score 40)16 were treated with ADC 15 (DAR 3.2).as treatment with a single i.v. dose of 1.4 mg/kg.
In Vivo Model Ovarian cancer PDX model (PDX: OV90)
Experiment 5 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 100.00% (Day 35) Low FOLR1 expression (FOLR1+)
Method Description
SCID mice bearing OV90 subcutaneous ovarian xenografts, which express folate receptor alpha heterogeneously, at a very low level (H-Score 40)16 were treated with ADC 15 (DAR 3.2).as treatment with a single i.v. dose of 2.7 mg/kg.
In Vivo Model Ovarian cancer PDX model (PDX: OV90)
Experiment 6 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 100.00% (Day 95) Low FOLR1 expression (FOLR1+)
Method Description
SCID mice bearing OV90 subcutaneous ovarian xenografts, which express folate receptor alpha heterogeneously, at a very low level (H-Score 40)16 were treated with ADC 15 (DAR 3.2).as treatment with a single i.v. dose of 2.7 mg/kg.
In Vivo Model Ovarian cancer PDX model (PDX: OV90)
References
Ref 1 Synthesis of Highly Potent N-10 Amino-Linked DNA-Alkylating Indolinobenzodiazepine Antibody-Drug Conjugates (ADCs). ACS Med Chem Lett. 2019 Jul 22;10(8):1211-1215. doi: 10.1021/acsmedchemlett.9b00254. eCollection 2019 Aug 8.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.